Our products



AND021 program is currently under clinical candidate nomination step. The small molecular candidate AND021 specifically binds to a pocket in HIF-2α and prevents HIF-2α and HIF-2β from forming transcriptionally functioning HIF-2 complex, thereby downregulating target genes. AND021 will be developed for HIF-2-dependent renal cell carcinoma and other difficult-to-treat diseases.